Alnylam Pharmace. diskutieren

Übersetzung fehlgeschlagen

Alnylan Pharmaceutics

pharma

tamam stimmt der Buy-Einschätzung von melinda zu

tamam stimmt am 20.09.2017 der Buy-Einschätzung von melinda mit dem Kursziel 85$ zu.
Überschrift: pharma

pharma

Biotechnologie und medizinische SecteurRecherche

Alnylam kontinuierliche Abgabe einer New Drug Application (NDA) bei der US Food and Drug Administration (FDA) für Patisiran in der Behandlung der hereditären ATTR - Amyloidose (hATTR) startet

Alnylam with its first new drug application and multiple clinical read-outs in 2018

Alnylam Pharmaceuticals (NASDAQ:ALNY) an Out of the Gate 2018 Pick at B. Riley FBR with a $205 (65% upside) price target citing expected positive FDA decision on patisiran in hATTR in July and expected positive Phase 3 data in porphyria (ENVISION study).

Alnylam had an active 2017, with its first new drug application (or NDA) submitted to the FDA and multiple clinical read-outs, and 2018 is likely to be no less busy. This new year should see the company get its first FDA approval and begin its first commercial launch, in additional to more incremental data on several programs, including data that could potentially support an NDA filing for givosiran before year-end. Moreover, management has not been shy about leveraging good news to raise funds, leaving the company with close to $1.7 billion in cash to start the year.

Hot Stock

SANOFI .occupé

Busy Sanofi einen Pass auf eines der Medikamente gegen seltene Krankheiten Alnylam nimmt, hat die FDA den Status „Durchbruch“ für PhIII